Heron Therapeutics, Inc. (HRTX)

Market Cap	188.54M -41.3%
Revenue (ttm)	154.90M +7.4%
Net Income	-20.20M
EPS	-0.12
Shares Out	188.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,630,943
Open	0.965
Previous Close	0.940
Day's Range	0.950 - 1.030
52-Week Range	0.736 - 2.610
Beta	1.42
Analysts	Strong Buy
Price Target	4.50 (+350.0%)
Earnings Date	May 5, 2026

About HRTX

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emeto...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 26, 1987
• Employees: 128
• Stock Exchange: NASDAQ
• Ticker Symbol: HRTX
• Website: https://www.herontx.com

Financial Performance

In 2025, Heron Therapeutics's revenue was $154.90 million, an increase of 7.36% compared to the previous year's $144.29 million. Losses were -$20.20 million, 48.7% more than in 2024.

Analyst Summary

According to 2 analysts, the average rating for HRTX stock is "Strong Buy." The 12-month stock price target is $4.5, which is an increase of 350.00% from the latest price.

Price Target

$4.5

(350.00% upside)

Analyst Consensus: Strong Buy